Previous 10 | Next 10 |
Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program PR Newswire -- FDA has provided clearance to the company to continue dosing patients who have already undergone lymphodepletion -- REDWOOD CITY, Calif. , June 19, 2023 /PRNews...
2023-06-02 10:02:23 ET Gainers: Connect Biopharma ( CNTB ) +26% . LAVA Therapeutics ( LVTX ) +19% . Panbela Therapeutics ( PBLA ) +18% . Apollomics ( APLM ) +15% . Rockwell Medical ( RMTI ) +10% . Losers: Kiora Pharm...
2023-05-08 17:05:24 ET Arcellx press release ( NASDAQ: ACLX ): Q1 GAAP EPS of -$0.58. Revenue of $17.91M. For further details see: Arcellx GAAP EPS of -$0.58, revenue of $17.91M
Arcellx Provides First Quarter Financial Results PR Newswire REDWOOD CITY, Calif. , May 8, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...
2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...
Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference PR Newswire REDWOOD CITY, Calif. , April 13, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development o...
Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights PR Newswire -- Signed strategic collaboration with Kite to co-develop and co-commercialize late-stage clinical CART-ddBCMA in multiple myeloma -- -- Presented continued robust long-te...
Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference PR Newswire REDWOOD CITY, Calif. , Feb. 21, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovativ...
H.C. Wainwright has initiated Arcellx ( NASDAQ: ACLX ) with a buy saying that the company's CAR-T therapies in development have advantages over marketed ones and its partnership with Gilead Sciences' ( GILD ) Kite Therapeutics will reap benefits. The firm has a $42 price target (~...
Arcellx to Participate in Upcoming Investor Conferences PR Newswire REDWOOD CITY, Calif. , Feb. 2, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patien...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 14:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 12:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...